VANCOUVER, BRITISH COLUMBIA, June 11, 2026 (GLOBE NEWSWIRE) — HI-VIEW RESOURCES INC. (“Hi-View” or the “Company”) (CSE: GXLD; OTCQB: GXLDF; FSE: B630) announces the receipt of two complementary satellite alteration mapping reports for its Toodoggone Portfolio claims in British Columbia, both prepared by PhotoSat Information Inc. The ASTER Alteration Mapping Report and the EnMAP Regional Hyperspectral Exploration Targeting Report together provide an advanced multi-sensor characterization of hydrothermal alteration across the property and will directly inform ground-based exploration targeting for the upcoming field season. Nader Mostaghimi, Vice President Exploration commented: “These data acquisitions represent a valuable addition to our exploration toolkit, supporting our vectoring efforts toward epithermal and porphyry mineralization...

Nokia introduces agentic AI framework in Network Services Platform to enable trust-based AI operations for IP networksNokia NSP adds an agentic AI framework that lets operators deploy AI agents grounded in a real-time, accurate network view — enabling them to reason based on trusted data and take guided, explainable actions within operator-defined policies and security boundaries. Nokia AI-driven Troubleshooting Agent accelerates root-cause analysis, reduces operational noise, and turns complex IP issues into guided, explainable workflows. Framework supports communication with external agents via new AI-based protocols across operators’ multi-vendor, multi-domain networks, empowering them on their journey toward fully autonomous networks.11 June 2026  Espoo, Finland – Nokia today announced an enhancement to its Network Services Platform...

Over half (54%) of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed—and nearly 40% do not carry one regularly (n=1,238 ).1 HCP survey data suggests only around half of patients consistently carry their prescribed AAI, with adherence perceived to be lowest among adolescents.2 EURneffy®, the only needle-free nasal adrenaline spray, was strongly and consistently preferred over AAIs by patients across four countries in a discrete choice experiment.1 In a simulated-use study, participants said they would find EURneffy® significantly easier to use and would act earlier than with an AAI.3New scientific data reveal serious shortcomings in the real-world management of anaphylaxis, with findings from two multi-country surveys suggesting that EURneffy®—the first and only approved needle-free...

23, Place des Carmes-Déchaux – 63000 CLERMONT-FERRAND Information about securities repurchasing programRegulated informationIssuer social denomination: Michelin – LEI 549300SOSI58J6VIW052 Types of securities: ordinary shares – Code ISIN FR001400AJ45Date : June 11th, 2026Issuer Name Issuer code Transactiondate ISIN Code Daily total volume (in number of actions) Daily weighted average price of shares acquired PlatformCompagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 11.06.2026 FR001400AJ45 213 797 30,6108 euros Over-the-counterCompagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 11.06.2026 FR001400AJ45 213 797 30,6108 euros Over-the-counterCompagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 11.06.2026 FR001400AJ45 213 797 30,6108 euros Over-the-counterIssuer Name Issuer...

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, presents final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preliminary data from the NATHALI-01 study evaluating eti-cel, a dual CD20 and CD22 directed CAR-T in relapsed/refractory B-cell non Hodgkin lymphoma (r/r B-NHL), at the European Hematology Association (EHA) 2026 Annual Congress. BALLI-01 clinical trial evaluating lasme-cel in r/r B-ALL – Oral Presentation The BALLI-01 final Phase 1 data will be presented as an oral presentation...

                            INSIDE INFORMATION NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering circular, or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017, as amended (the “Prospectus Regulation”) and nothing herein shall be construed as an offering of securities. The offer to acquire securities pursuant to the offering of shares in InstallatørGruppen A/S is, and any investment decision by an investor should be made, solely on the basis of information that is contained in the offering circular or prospectus, which is made generally available in Denmark in connection with the offering....

EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activation The vaccine antigens drive specific immune responses across different human immune profiles and induce targeted cell-killing Poster presentation at the European Hematology Association (EHA) 2026 Congress, taking place in Stockholm, SwedenCOPENHAGEN, Denmark, June 11, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology™, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome. The new data demonstrates EVX-04’s complete expression...

ORLANDO, June 11, 2026 (GLOBE NEWSWIRE) — PureCycle Technologies, Inc. (“PureCycle” or “we,” “our” or “us”) (Nasdaq: PCT) today announced the pricing of its previously announced underwritten public offerings of $250.0 million aggregate principal amount of its 4.75% convertible senior notes due 2032 (the “notes” and such offering, the “Notes Offering”), and, concurrently, 17,661,388 shares of its common stock, par value $0.001 per share (the “common stock”; such offering, the “Common Stock Offering” and, together with the Notes Offering, the “Offerings”), at a public offering price of $8.21 per share, for aggregate gross proceeds of $395.0 million. In addition, PureCycle has granted (i) the underwriters in the Notes Offering a 30-day option to purchase up to an additional $37.5 million aggregate principal amount of notes, solely...

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering circular, or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017, as amended (the “Prospectus Regulation”) and nothing herein shall be construed as an offering of securities. The offer to acquire securities pursuant to the offering of shares in InstallatørGruppen A/S (“InstallatørGruppen” or the “Company”) will be made, and any investment decision by an investor should be made, solely on the basis of information that is contained in the offering circular or prospectus, which is made generally available in Denmark in connection with the...

INSIDE INFORMATION NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering circular, or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017, as amended (the “Prospectus Regulation”) and nothing herein shall be construed as an offering of securities. The offer to acquire securities pursuant to the offering of shares in InstallatørGruppen A/S is, and any investment decision by an investor should be made, solely on the basis of information that is contained in the offering circular or prospectus, which is made generally available in Denmark in connection with the offering. Copies of the offering...